Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 340

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 340
---
8808,278 2029832,527 Thereafter2,041,704 Total future lease payments5,601,720 Less: Imputed interest(1,601,160)Total lease liabilities$4,000,560 Lease liabilities$366,959 Lease liabilities, net of current portion3,633,601 Total lease liabilities$4,000,560 Quantitative information regarding the Company’s leases for the six months ended June 30, 2025 and 2024 is as follows:June 30,2025June 30,2024Lease costs:Operating lease cost$373,180 $387,642 Short-term lease cost67,656 79,878 Sublease income— (19,200)Total lease costs$440,836 $448,320 Cash paid for amounts included in the measurement of lease liabilities:  Operating cash flows from operating leases$367,092 $370,800 Operating cash flows from short-term leases67,656 79,878 $434,748 $450,678 Weighted-average remaining lease term - operating leases6.84 years7.84 yearsWeighted-average discount rate - operating leases10.0 %10.0 %As the Company’s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.LitigationFrom time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities and may be exposed to litigation in connection with its product candidates and operations. The Company’s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. When it is probable that future expenditures will be made and can be reasonably estimated the Company will accrue a liability for such matters. Significant judgement is required to determine both probability and estimated amount. The Company is not aware of any material legal matters.

21

Clinical Research ContractsThe Company may enter into contracts in the normal course of business with contract research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for the Company’s operating purposes. These contracts generally provide for termination with a 30-day notice.

Note 11 – Segments 

Operating segments are identified as components of an enterprise about which separate discrete financial information is